Search
for
Sort by
Research 871–900 of 1000+
- Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes
- Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF‐κB‐ and MAPK‐ERK1/2‐mediated COX‐2 expression
- Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
- Effects of two estroprogestins containing ethynilestradiol 30mug and drospirenone 3 mg and ethynilestradiol 30mug and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations
- Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
- Menopause, skin and common dermatoses. Part 2: skin disorders
- Cloning, expression and characterization of rhesus macaque types 1 and 2 5alpha-Reductase: evidence for mechanism-Based inhibition by finasteride
- A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS‐CoV‐2 vaccine
- An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia
- Dermatologic care of sexual and gender minority/LGBTQIA youth, Part 2: Recognition and management of the unique dermatologic needs of SGM adolescents
- FUT vs. FUE Graft Survival: A Side-by-Side Study of 3 Patients Undergoing a Routine 2,000+ Graft Hair Transplantation
- Lack of evidence of a role for the neurosteroid allopregnanolone in ethanol-induced reward and c-fos expression in DBA/2 mice
- Post-COVID-19 Sydrome and Decrease in Health-Related Quality of Life in Kidney Transplant Recipients after SARS-COV-2 Infection—A Cohort Longitudinal Study from the North of Poland
- New effects of caffeine on corticotropin‐releasing hormone (CRH)‐induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH‐R1/2, IP<sub>3</sub>‐R, ACTH, MC‐R2) and the neurogenic non‐HPA axis (substance P, p75<sup>NTR</sup>and TrkA) in<i>ex vivo</i>human male androgenetic scalp hair follicles
- Complications Post-COVID-19 and Risk Factors among Patients after Six Months of a SARS-CoV-2 Infection: A Population-Based Prospective Cohort Study
- Immunofluorescence Tomography: High-resolution 3-D reconstruction by serial-sectioning of methacrylate embedded tissues and alignment of 2-D immunofluorescence images
- A novel point mutation of keratin 17 (<i>KRT17</i>) in a Japanese family with pachyonychia congenita type 2: an RNA-based genetic analysis using a single hair bulb
- Alopecia areata; combination therapy with isotretinoin (0.05%) gel and minoxidil (2%) solution
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- Dermatology, ed. 2
- Computational metal-flavonoids complexes presentation of greenly synthesized silver nanoparticles combined flavonoids from <i>Lens culinaris L.</i> as anticancer agents using BcL-2 and IspC proteins
- In silico screening of Moroccan medicinal plants with the ability to directly inhibit the novel coronavirus, SARS-CoV-2
- A Powerful Method for Pleiotropic Analysis under Composite Null Hypothesis Identifies Novel Shared Loci Between Type 2 Diabetes and Prostate Cancer
- Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
- Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus
- Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy
- Reversal of premature hair graying treated with a topical formulation containing α-melanocyte-stimulating hormone agonist (Greyverse Solution 2%)
- Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial
- Multi-target evaluation of Korean herbal compounds against the SRD5A2 / AR / beta-catenin axis for androgenetic alopecia: Boltz-2 cofold, ChEMBL-anchored ranking, ADMET-AI 107-endpoint safety panel, and pilosebaceous single-cell atlas-constrained prioritization of Saponin Re, Emodin, and Biochanin A